Premium
A placebo‐controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol
Author(s) -
Rolan P.,
Terpstra I. J.,
Clarke C.,
Mullins F.,
Visser J. N.
Publication year - 2003
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.2003.01793.x
Subject(s) - acenocoumarol , tamsulosin , pharmacokinetics , pharmacodynamics , placebo , medicine , pharmacology , anesthesia , warfarin , atrial fibrillation , alternative medicine , pathology , hyperplasia
AimTo evaluate pharmacokinetic and pharmacodynamic interactions between tamsulosin and acenocoumarol.MethodsTwelve healthy volunteers received tamsulosin 0.4 mg or placebo once daily for 9 days in a double‐blind, cross‐over study. On day 5 of each study period, a single 10‐mg oral dose of racemic acenocoumarol was administered.ResultsThe ratios (point estimates (90% confidence intervals)) of values in the presence and absence of tamsulosin were: AUC PT 1.01 (0.98, 1.03); maximum prothrombin time (Pt max ) 0.99 (0.94, 1.05); AUC (R)‐acenocoumarol 1.02 (0.90, 1.16), and AUC (S)‐acenocoumarol 1.03 (0.89, 1.20). Both combinations, tamsulosin and placebo with acenocoumarol, were well‐tolerated.ConclusionsMultiple doses of tamsulosin had no effect on the pharmacokinetics or pharmacodynamics of a single high dose of acenocoumarol.